CN116806887A - Fat composition for accelerating fat metabolism and preparation method thereof - Google Patents
Fat composition for accelerating fat metabolism and preparation method thereof Download PDFInfo
- Publication number
- CN116806887A CN116806887A CN202310880705.6A CN202310880705A CN116806887A CN 116806887 A CN116806887 A CN 116806887A CN 202310880705 A CN202310880705 A CN 202310880705A CN 116806887 A CN116806887 A CN 116806887A
- Authority
- CN
- China
- Prior art keywords
- parts
- microcapsule powder
- powder
- oil
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000004060 metabolic process Effects 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 100
- 239000003094 microcapsule Substances 0.000 claims abstract description 82
- 235000019197 fats Nutrition 0.000 claims abstract description 54
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 42
- 239000003921 oil Substances 0.000 claims abstract description 40
- 235000019198 oils Nutrition 0.000 claims abstract description 40
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 25
- 239000003240 coconut oil Substances 0.000 claims abstract description 25
- 235000014121 butter Nutrition 0.000 claims abstract description 22
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 21
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 21
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 10
- 239000004519 grease Substances 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000008601 oleoresin Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000001603 reducing effect Effects 0.000 abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 6
- 239000008103 glucose Substances 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 150000001720 carbohydrates Chemical class 0.000 abstract description 3
- 235000014633 carbohydrates Nutrition 0.000 abstract description 3
- 150000002576 ketones Chemical class 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 21
- 235000005911 diet Nutrition 0.000 description 20
- 230000037213 diet Effects 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 8
- 235000005686 eating Nutrition 0.000 description 8
- 235000021590 normal diet Nutrition 0.000 description 8
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 235000019577 caloric intake Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 235000020855 low-carbohydrate diet Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000013116 obese mouse model Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a grease composition for accelerating fat metabolism and a preparation method thereof, comprising the following steps: 20-30 parts of virgin coconut oil microcapsule powder, 10-20 parts of butter microcapsule powder, 10-20 parts of diglyceride microcapsule powder, 5-10 parts of medium chain triglyceride microcapsule powder, 3-8 parts of arachidonic acid grease powder and 1-5 parts of vine fruit oil. The grease composition plays a synergistic role in increasing fat content and reducing carbohydrate content through the mutual compatibility of the raw materials, and ketone body is used for replacing glucose for supplying energy, so that sugar intake is reduced, and the effect of losing weight is achieved.
Description
Technical Field
The invention relates to the technical field of foods, in particular to a grease composition for accelerating fat metabolism and a preparation method thereof.
Background
With the increase of the economy and the improvement of the living standard of people in China, the lack of eating habits and sports with high fat and high heat can lead to the increase of the obesity rate by increasing the overweight and obese people. However, conventional weight loss methods generally require a limitation of calorie intake, and such methods often leave people in a hungry state, and light is difficult to keep on. In addition, in the state of high-carbohydrate diet, blood sugar and insulin are always in the circulation of large and large, which easily causes appetite to be large and large, resulting in eating disorder.
The high fat low carbohydrate diet is a special diet formulation and contains high fat, low carbohydrate, protein and other nutrients. Compared with the common diet, the diets mainly depend on ketone bodies produced by fat oxidation to produce energy (non-sugar aerobic oxidation energy supply). High fat low carbohydrate diets were first used to treat pediatric refractory seizures and have proven to have substantial relief from seizures. The high fat low carbon water diet is also used for treating Alzheimer's disease, diabetes and other diseases in the later period. Many studies have shown that low-carbohydrate diets are more effective in weight loss than low-fat diets, and thus, more and more people use high-fat low-carbohydrate diets as a diet method for weight control and to achieve a certain effect.
At present, animal and vegetable grease with long-chain fatty acid is mainly used in daily diet of people, obesity easily caused by excessive intake of animal and vegetable grease cannot achieve the effects of losing weight and reducing fat, and the animal and vegetable grease has no health care effect, such as losing weight, reducing fat or assisting in reducing blood sugar, and the like, is single in type, single in raw material and poor in market prospect.
Therefore, how to provide a fat and oil composition for accelerating fat metabolism is a technical problem to be solved by those skilled in the art.
Disclosure of Invention
In view of the above, the present invention provides a fat composition for accelerating fat metabolism and a method for preparing the same.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
a fat composition for accelerating fat metabolism, comprising: 20-30 parts of virgin coconut oil microcapsule powder, 10-20 parts of butter microcapsule powder, 10-20 parts of diglyceride microcapsule powder, 5-10 parts of medium chain triglyceride microcapsule powder, 3-8 parts of arachidonic acid grease powder and 1-5 parts of vine fruit oil.
Preferably, it comprises: 10 parts of virgin coconut oil microcapsule powder, 16 parts of butter microcapsule powder, 16 parts of diglyceride microcapsule powder, 8 parts of medium chain triglyceride microcapsule powder, 8 parts of arachidonic acid oil powder and 3 parts of merry-go-round oil.
Preferably, it comprises: 24 parts of virgin coconut oil microcapsule powder, 8 parts of butter microcapsule powder, 10 parts of diglyceride microcapsule powder, 5 parts of medium chain triglyceride microcapsule powder, 5 parts of arachidonic acid oil powder and 2 parts of merry-go-round oil.
Preferably, it comprises: 30 parts of virgin coconut oil microcapsule powder, 20 parts of butter microcapsule powder, 18 parts of diglyceride microcapsule powder, 6 parts of medium chain triglyceride microcapsule powder, 3 parts of arachidonic acid oil powder and 5 parts of merry-go-round oil.
The main component of coconut oil is lauric acid, which is also the main component of fat in breast milk. Lauric acid can improve immunity of human body, has strong antibacterial effect against bacteria and viruses in human body, even parasites in intestinal tract and gastric tract, and is suitable for children, the elderly and people with weak body constitution with insufficient resistance and easy infection. Can reduce cholesterol ratio, and prevent and treat heart disease and other cardiovascular diseases without increasing body metabolic load. Coconut oil helps to increase insulin sensitivity, make cells more responsive and less antagonistic, thus helping to protect against hypertension, even reduce blood pressure, and reduce the risk of heart disease. Therefore, the coconut oil can not accumulate on the wall of a blood vessel to cause arteriosclerosis, so that vascular diseases are reduced, the coconut oil is saturated fat, the lipid is stable, and free radical attack is not easy to oxidize. The coconut oil can be used for caring skin, resisting aging, and resisting oxidation, and can help human body to prevent free radical generation.
The butter has high fat content, contains nutrients such as vitamins, minerals and proteins, and improves human immunity, and the butter microcapsule powder is a powdery substance formed by wrapping solid, liquid or gas substances by high-quality wall materials by utilizing a microcapsule technology. The diameter is 1-500 mu m, the thickness of the wall is generally 0.5-150 mu m, the stability of the product can be improved, the mutual interference among various components is prevented, and the product is easier to be absorbed and utilized by human bodies.
The main components of diglyceride are 1,3-DAG (usually 28% or more), triglyceride (TAG), 1,2-DAG (2, 3-DAG), etc.; DAG is taken as 1 natural oil component, has unique nutrition characteristics, and the dietary DAG oil can obviously reduce the body mass and body fat level of a human body by improving energy balance, increasing energy consumption or reducing energy intake, and simultaneously exert other various health effects.
Medium chain triglycerides consist only of saturated fatty acids, with high fat content;
arachidonic acid is an essential fatty acid of the human body, which is a polyunsaturated fatty acid, and exists in the body mainly in the form of phospholipids on cell membranes, which can increase intracellular Ca 2+ Concentration, modulating cellular function; arachidonic acid can directly activate protein kinase C and phospholipase C, promote brain cell growth, activate and inhibit platelet aggregation, participate in immunomodulation, induction and inhibit cell differentiation, and also can regulate blood sugar and blood lipid.
The Meinauguration seed oil contains abundant unsaturated fatty acid, and also contains various antioxidant active substances such as vitamin E, phenolic compounds, sterols, terpenes, flavonoids and the like, and has the effects of resisting oxidation, reducing blood sugar and fat, inhibiting cancer cell proliferation and the like; the Meinaria oil can reduce the total cholesterol content of serum and the low-density lipoprotein cholesterol content and increase the high-density lipoprotein cholesterol content and the total protein content, thereby achieving the effect of regulating blood fat.
As the same inventive concept as the above technical solution, the present invention also claims any one of the preparation methods of the fat composition for accelerating fat metabolism, comprising the following steps:
1) Weighing: weighing the virgin coconut oil microcapsule powder, the butter microcapsule powder, the diglyceride microcapsule powder, the medium chain triglyceride microcapsule powder, the arachidonic acid oleoresin powder and the vine fruit oil according to the weight parts for standby.
2) Adding water into the pre-pressed coconut oil microcapsule powder and butter microcapsule powder according to the mass ratio of 1:5, mixing, and pouring into a stirring pot for stirring to obtain a mixture;
3) Adding diglyceride microcapsule powder, medium chain triglyceride microcapsule powder, arachidonic acid oil fat powder and Meinao fruit oil into the mixture, heating to 60-80deg.C, keeping the temperature for 24 hr, and stirring to obtain oil composition.
According to the technical scheme, the composition is selected, namely the raw material ratio of high fat to high protein is selected, and specifically, the virgin coconut oil microcapsule powder, the butter microcapsule powder and the medium chain triglyceride microcapsule powder have higher fatty acid content; diglycerides have unique nutritional properties that can significantly reduce body fat levels in the human body by increasing energy expenditure or reducing energy intake; the Meinaria oil contains a large amount of antioxidant active substances, so that free radicals can be removed, and the metabolism level of fat can be improved. That is, the fat composition for accelerating fat metabolism provided by the invention has a synergistic effect in increasing fat content and reducing carbohydrate content through the mutual compatibility of raw materials, and can reduce sugar intake by replacing glucose with ketone body, thereby achieving the effect of losing weight.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The raw materials used in the examples are all commercially available.
Example 1
A fat composition for accelerating fat metabolism, comprising: 10 parts of virgin coconut oil microcapsule powder, 16 parts of butter microcapsule powder, 16 parts of diglyceride microcapsule powder, 8 parts of medium chain triglyceride microcapsule powder, 8 parts of arachidonic acid oil powder and 3 parts of merry-go-round oil.
Example 2
A fat composition for accelerating fat metabolism, comprising: 24 parts of virgin coconut oil microcapsule powder, 8 parts of butter microcapsule powder, 10 parts of diglyceride microcapsule powder, 5 parts of medium chain triglyceride microcapsule powder, 5 parts of arachidonic acid oil powder and 2 parts of merry-go-round oil.
Example 3
A fat composition for accelerating fat metabolism, comprising: 30 parts of virgin coconut oil microcapsule powder, 20 parts of butter microcapsule powder, 18 parts of diglyceride microcapsule powder, 6 parts of medium chain triglyceride microcapsule powder, 3 parts of arachidonic acid oil powder and 5 parts of merry-go-round oil.
The preparation method of the solid beverage comprises the following steps:
1) Weighing: weighing the virgin coconut oil microcapsule powder, the butter microcapsule powder, the diglyceride microcapsule powder, the medium chain triglyceride microcapsule powder, the arachidonic acid oleoresin powder and the vine fruit oil according to the weight parts for standby.
2) Adding water into the pre-pressed coconut oil microcapsule powder and butter microcapsule powder according to the mass ratio of 1:5, mixing, and pouring into a stirring pot for stirring to obtain a mixture;
3) Adding diglyceride microcapsule powder, medium chain triglyceride microcapsule powder, arachidonic acid oil fat powder and Meinao fruit oil into the mixture, heating to 60-80deg.C, keeping the temperature for 24 hr, and stirring to obtain oil composition.
Comparative example 1
Compared with the embodiment 2, the virgin coconut oil microcapsule powder is removed, and the proportion of the rest components is unchanged;
comparative example 2
Compared with the example 2, the butter microcapsule powder is removed, and the proportion of the rest components is unchanged;
comparative example 3
Compared with the example 2, the microcapsule powder of the diglyceride microcapsule powder is removed, and the proportion of the rest components is unchanged;
comparative example 4
Compared with the embodiment 2, the medium chain triglyceride microcapsule powder is removed, and the proportion of the rest components is unchanged;
comparative example 5
Compared with the embodiment 2, the arachidonic acid oil powder is removed, and the proportion of the rest components is unchanged;
comparative example 6
Compared with the example 2, the Meinaria fruit oil is removed, and the proportion of the other components is unchanged.
SPF-class male C57 rats (160) were selected and randomly divided into 2 groups, one group being a model group, 150, and the other group being a blank group, 10 mice in total. The basal feed is given to the blank group, after the mice of the model group are fed with the high-calorie feed for 2 weeks, the obese resistant mice at the lower 1/3 of the mice are removed according to the sequence from the big to the small of the weight, and the obese mice at the upper 2/3 of the mice are screened for subsequent experiments. The obese mice were fed high calorie diet for 6 weeks and an obese mouse model was established. The blank group was always fed basal feed. The obese model mice were randomized into 10 groups, 10 each, and 9 of them were administered as test groups with the compositions of examples 1-3 and comparative examples 1-6, respectively, and the test groups were given with 0.5g/kg of the corresponding products per day by gastric lavage, and the model control group was given with an equivalent amount of physiological saline, and the mice were still free to ingest high fat diet during the administration period. The weight of the mice was recorded daily from the start of dosing, anesthetized by week 6, dissected for perirenal fat, peritesticular fat and weighed, the average of the weights at different time periods was calculated and the statistical weight gain after the end of the experiment was recorded, and the test results are shown in tables 1-2.
TABLE 1
TABLE 2
| Abdomen fat weight (g) of sixth week mice | |
| Blank control group | 10.28 |
| Model control group | 21.37 |
| Example 1 | 15.24 |
| Example 2 | 15.49 |
| Example 3 | 14.37 |
| Comparative example 1 | 17.52 |
| Comparative example 2 | 18.15 |
| Comparative example 3 | 18.59 |
| Comparative example 4 | 17.69 |
| Comparative example 5 | 18.88 |
| Comparative example 6 | 19.21 |
As can be seen from tables 1-2, the weight gain rate during the experiment in the mice in the model group was as high as 25.1% due to high caloric intake, and the experimental model was successfully constructed, whereas the compositions of examples 1-3 of the present invention were effective in inhibiting the weight gain rate of the mice in comparison with the model group, wherein the composition of the experimental group 3 resulted in the weight gain rate of the mice of only 8.9% and the fat mass after the experiment of only about 14.37g. However, when any of the ingredients of the present invention are removed, the weight gain rate and fat weight are significantly lower than in the compositions of the present invention. It can be shown that the composition of the present invention has an effect of inhibiting weight gain and also reduces fat absorption and accumulation, and that the composition of the present invention does not achieve any of the effects by removing any of the components, indicating that the components of the present invention act together.
Example 4
As test samples, 60 male ICR mice (20+ -2 g) were selected, and were randomly divided into 2 groups, one group was a model group, 55 mice were included in the other group, and 5 mice were included in the other group. 55 mice were fasted for 10 hours and 2% of a 2% solution of tetraoxypyrimidine was injected intraperitoneally at 200mg/kg (the first injection amount was 70% of the total amount, the second injection amount was 30% of the total amount, and the two times were 12 hours apart). After 3 days, the tail is broken after 12 hours of fasting, blood sugar and weight of the mice are measured, 40 mice with the empty abdomen blood sugar value of more than 11mmol/l are screened, and the mice are randomly divided into 8 groups, and 5 mice are in each group. The test group was perfused with 0.5g/kg of the corresponding composition per day, and the blank control group and the model control group were administered with an equal amount of physiological saline for 10 consecutive days, during which time blood was taken by periodic tail breaking, and blood glucose and serum insulin were measured in mice after 12h of fasting.
TABLE 3 Table 3
As shown in Table 3, the blood glucose level of mice was significantly increased by intraperitoneal injection of tetraoxypyrimidine for 72 hours, and after continuous gastric lavage for 10 days in the sample group, postprandial blood glucose was reduced to a different extent in each group compared with the model control group, thus demonstrating that the composition of the present invention has a better blood glucose reducing effect.
Example 5
140 obese volunteers with BMI in the range of 25-29.9 were selected, and the compositions of examples 1-3 and comparative examples 1-6 were taken as meal replacement drinks for dinner, 30g of each diet was taken with 100ml of water;
140 volunteers were randomly divided into 7 groups of 20 persons, each group being example 3, comparative example 1, comparative example 2, comparative example 3, comparative example 4, comparative example 5, comparative example 6, and after two months, the number of people who reduced the body weight by 2-8%, 8-10% and reduced the body weight by 10-15% was counted for each group, as shown in Table 4;
TABLE 4 Table 4
As can be seen from Table 4, the composition of the present invention can achieve a significant weight reduction effect, while the weight of each group in the comparative example is significantly lower than that in example 3, although the weight is reduced. Therefore, the composition can play a synergistic effect and realize a better weight-losing effect.
Example 6
40 obese volunteers with BMI in the range of 25-29.9 were selected and randomized into 4 groups of 10 individuals each, each group being a normal diet group, normal diet + eating the composition of example 3, controlled diet group (daily intake control at 1500 Kcal), controlled diet + eating the composition of example 3. Wherein the composition of example 3 was taken as a meal replacement drink for dinner, 30g daily, with 100ml water, without deliberate exercise increase throughout the experiment, and with other diet foods and medicines prohibited. After one month, the body weight, body fat percentage, and the like of each group of subjects were counted, and are shown in tables 5 to 6;
TABLE 5 weight change of subjects before and after the experiment
| Before the experiment (kg) | After the experiment (kg) | |
| Normal diet group | 68.64 | 71.58 |
| Normal diet + eating example 3 | 68.73 | 62.14 |
| Diet control group | 68.91 | 66.05 |
| Controlled diet + eating example 3 | 68.76 | 61.07 |
TABLE 6 results of percent body fat detection in subjects
| Before the experiment (%) | Post-experiment (%) | |
| Normal diet group | 29.45 | 29.68 |
| Normal diet + eating example 3 | 29.88 | 23.32 |
| Diet control group | 29.67 | 27.69 |
| Controlled diet + eating example 3 | 29.81 | 21.84 |
As can be seen from tables 5 and 6, the composition of the present invention can accelerate metabolism of the body and increase the ability of burning heat, and can accelerate utilization of fat without intentional exercise, and in this experiment, the body weight and body fat of the subject are significantly reduced after eating the composition of example 3 compared to the normal diet group; after eating the composition of example 3 under controlled diet, the body weight and body fat of the subject were significantly reduced compared to the diet alone. In addition, the composition of the invention can reduce the weight and body fat without significant difference on the premise of controlling diet or normal diet. Therefore, after the composition provided by the invention is taken by a subject, the weight is reduced, the fat is reduced, the percentage of body fat is reduced, and the purpose of reducing the fat is achieved, so that the composition has a synergistic effect.
In the present specification, each embodiment is described in a progressive manner, and each embodiment is mainly described in a different point from other embodiments, and identical and similar parts between the embodiments are all enough to refer to each other.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (5)
1. A fat composition for accelerating fat metabolism, comprising: 20-30 parts of virgin coconut oil microcapsule powder, 10-20 parts of butter microcapsule powder, 10-20 parts of diglyceride microcapsule powder, 5-10 parts of medium chain triglyceride microcapsule powder, 3-8 parts of arachidonic acid grease powder and 1-5 parts of vine fruit oil.
2. A fat composition for accelerating fat metabolism according to claim 1, comprising: 10 parts of virgin coconut oil microcapsule powder, 16 parts of butter microcapsule powder, 16 parts of diglyceride microcapsule powder, 8 parts of medium chain triglyceride microcapsule powder, 8 parts of arachidonic acid oil powder and 3 parts of merry-go-round oil.
3. A fat composition for accelerating fat metabolism according to claim 1, comprising: 24 parts of virgin coconut oil microcapsule powder, 8 parts of butter microcapsule powder, 10 parts of diglyceride microcapsule powder, 5 parts of medium chain triglyceride microcapsule powder, 5 parts of arachidonic acid oil powder and 2 parts of merry-go-round oil.
4. A fat composition for accelerating fat metabolism according to claim 1, comprising: 30 parts of virgin coconut oil microcapsule powder, 20 parts of butter microcapsule powder, 18 parts of diglyceride microcapsule powder, 6 parts of medium chain triglyceride microcapsule powder, 3 parts of arachidonic acid oil powder and 5 parts of merry-go-round oil.
5. The method for producing a fat composition for accelerating fat metabolism according to any one of claims 1 to 4, comprising the steps of:
1) Weighing: weighing the virgin coconut oil microcapsule powder, the butter microcapsule powder, the diglyceride microcapsule powder, the medium chain triglyceride microcapsule powder, the arachidonic acid oleoresin powder and the vine fruit oil according to the weight parts for standby.
2) Adding water into the pre-pressed coconut oil microcapsule powder and butter microcapsule powder according to the mass ratio of 1:5, mixing, and pouring into a stirring pot for stirring to obtain a mixture;
3) Adding diglyceride microcapsule powder, medium chain triglyceride microcapsule powder, arachidonic acid oil fat powder and Meinao fruit oil into the mixture, heating to 60-80deg.C, keeping the temperature for 24 hr, and stirring to obtain oil composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310880705.6A CN116806887A (en) | 2023-07-18 | 2023-07-18 | Fat composition for accelerating fat metabolism and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310880705.6A CN116806887A (en) | 2023-07-18 | 2023-07-18 | Fat composition for accelerating fat metabolism and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116806887A true CN116806887A (en) | 2023-09-29 |
Family
ID=88112804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310880705.6A Pending CN116806887A (en) | 2023-07-18 | 2023-07-18 | Fat composition for accelerating fat metabolism and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116806887A (en) |
-
2023
- 2023-07-18 CN CN202310880705.6A patent/CN116806887A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5335192B2 (en) | Novel dietary supplement composition and use thereof | |
| CN111084381A (en) | Ketogenic nutritional meal replacement powder and application | |
| CN108720021A (en) | DHA algal oil microscapsule powder and preparation method thereof | |
| CN110810845A (en) | Total nutrient formula powder with ketogenesis, fat reduction and sugar resistance functions and application thereof | |
| CN105707292A (en) | Camellia blend oil suitable for infants | |
| CN108703364A (en) | Treating fatty acid metabolism tailored version clinical nutrition formula and preparation method thereof | |
| KR20020090229A (en) | Starch sub-types and lipid metabolism | |
| CN113287659A (en) | Functional structural oil and preparation method and application thereof | |
| CN111728195A (en) | Low-carbon non-ketogenic fat-reducing and sugar-reducing meal-replacement milk shake and preparation method thereof | |
| CN110810468B (en) | Ketogenic cookies and preparation method thereof | |
| CN102090453A (en) | Weight-reducing and beautifying milk tea | |
| CN101849585A (en) | Functional nutrient plant blend oil and preparation method thereof | |
| CN112189839A (en) | Composition for assisting in reducing blood fat and application thereof | |
| WO2008140064A1 (en) | Nutrient composition for prevention and amelioration of lifestyle-related disease | |
| CN116806887A (en) | Fat composition for accelerating fat metabolism and preparation method thereof | |
| JP2002302441A (en) | Composition and food and drink for obtunding symptom of premenstrual syndrome | |
| CN111557365A (en) | Combined functional chocolate and preparation method thereof | |
| CN115462526A (en) | Weight management composition containing plant exosomes | |
| CN112890066A (en) | Solid beverage capable of regulating blood fat, resisting fatigue and enhancing immunity and application thereof | |
| CN109601987A (en) | A kind of microcapsule powder, wet nurse's nutrient supplement food and preparation method thereof | |
| CN111513145A (en) | Edible blend oil containing lutein ester and preparation method thereof | |
| CN115413787B (en) | Composition and application thereof | |
| JP6470879B1 (en) | Anti-inflammatory agent, anti-inflammatory pharmaceutical composition, anti-inflammatory food composition | |
| CN110115330A (en) | It is a kind of to contain chlorella, turmeric and beverage of natural inulin and preparation method thereof | |
| WO2022202566A1 (en) | Method for raising blood decanoic acid concentration, blood-decanoic-acid-concentration-raising agent, pharmaceutical composition, and food composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |